Actively Recruiting
CoPenhagen Heart Failure With Preserved Ejection Fraction (CPH-HFpEF)
Led by Tor Biering-Sørensen · Updated on 2025-03-05
5000
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure with preserved ejection fraction (HFpEF) is becoming the most common form of heart failure worldwide, especially among older adults and those with conditions like obesity, diabetes, and hypertension. HFpEF is linked to high rates of illness, death, and hospitalizations, posing a major health challenge. Despite its prevalence, HFpEF often goes undiagnosed, highlighting the need for better identification and management strategies. This study is a prospective, observational cohort design that uses Danish National Health Registries to identify up to 5000 individuals aged 50 to 89 living in the Capital Region of Denmark who have risk factors for HFpEF. Recruitment is conducted by sending invitation letters through a secure electronic mailbox linked to participants' social security numbers. The study focuses on evaluating the screening and identification processes for HFpEF and understanding participants' willingness to join the study. Participants will be monitored from the invitation date for about 12 months to assess the screening procedures. Researchers will measure how many eligible adults agree to participate and identify any barriers to involvement. The study will also analyze data until March 2026 to help improve future efforts in finding and enrolling patients with HFpEF, especially those who are vulnerable.
CONDITIONS
Brief Title
Copenhagen Heart Failure With Preserved Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Residence in the Capital Region of Denmark
- Age 50 years or older
- At least two risk factors for HFpEF (for age 60 or older, only one risk factor is needed). Risk factors include hypertension, diabetes mellitus, chronic kidney disease, atrial fibrillation, BMI over 25 kg/m2, previous heart valve surgery, ischemic heart disease, obstructive sleep apnea, or use of furosemide 40 mg
You will not qualify if you...
- Age 90 years or older
- Existing heart failure diagnosis
- Dementia
- Living in a nursing home
- Amyloidosis
- Receiving hemodialysis
- Cancer diagnosed within the past 5 years (excluding skin cancer)
- Prior solid organ transplantation
- Lung diseases such as WHO Group 1 pulmonary hypertension, chronic pulmonary embolism, lung fibrosis, COPD, or use of home oxygen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - Up to 12 months
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 12 months
Participants with risk factors for HFpEF are observed to evaluate identification and screening procedures and to assess willingness to participate and address barriers.
Trial Site Locations
Total: 1 location
1
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital
Hellerup, Denmark, 2900
Actively Recruiting
Research Team
C
Camilla I Ottosen, MD
T
Tor Biering-Sørensen, MD, MPH, MSc, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here